Fresenius to Improve Care for Chronic Kidney Disease in Mexico

Fresenius Medical Care, which develops products and services for individuals with renal diseases, is expanding access to High-Volume Hemodiafiltration (HighVolumeHDF) in seven of the 10 centers across Mexico. The expansion comes through a partnership with the Coordination of the National Institutes of Health and High Specialty Hospitals (CCINSHAE) in Mexico. This initiative aims to provide low-income patients without medical coverage in Mexico with access to advanced dialysis therapies, especially those with chronic kidney disease (CKD).

“This innovative pilot program, aimed at providing CDK patients with access to high-quality treatments that were previously out of reach, represents a major breakthrough in the treatment of CKD in Mexico,” says Edgar Robles, General Director of Commercial Operations at Care Enablement, Fresenius Medical Care Mexico.

The partnership includes a two-year contract between Fresenius Medical Care Mexico and CCINSHAE, which will enable the installation of 150 5008S CorDiax systems at participating renal treatment centers in Mexico City and its metropolitan area. The move marks a significant step in improving access to life-saving treatments for patients suffering from CKD.

The 5008S CorDiax technology enables both standard hemodialysis and HighVolumeHDF, a scientifically backed therapy that has proven to reduce mortality, improve patient well-being, and increase cost-effectiveness in most healthcare systems. As part of the collaboration, 240 uninsured patients at CCINSHAE have recently received HighVolumeHDF treatment. In addition, 410 patients with public or private insurance across Mexico began receiving this therapy last year.

Many of these patients were transitioned from CCINSHAE’s hemodialysis program to HighVolumeHDF, while others were newly assigned to the centers due to recent diagnoses, shifts from peritoneal dialysis to hemodiafiltration, or entry into transplant programs. The expansion of HighVolumeHDF has doubled the number of patients receiving this advanced treatment.

"Fresenius Medical Care is committed to expanding access to innovative therapies like HighVolumeHDF," says Robles. "Our focus is on raising the standards of dialysis care, enhancing patient quality of life, simplifying operational procedures, and providing efficient hemodialysis solutions for healthcare professionals."

HighVolumeHDF has been supported by multiple clinical studies, including the international randomized and controlled CONVINCE trial, which compared HighVolumeHDF with standard high-flow hemodialysis. The study reported a 23% reduction in all-cause mortality in patients treated with HighVolumeHDF compared to those receiving standard high-flow hemodialysis.

Fresenius Medical Care’s HighVolumeHDF therapy is available now in several countries across Latin America, including Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Panama, Peru, and Uruguay. CCINSHAE is part of Mexico's public healthcare system, which serves as a key player in providing critical health services to the population.